Scott McPhee

3.0k total citations
27 papers, 2.2k citations indexed

About

Scott McPhee is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Scott McPhee has authored 27 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Genetics and 7 papers in Oncology. Recurrent topics in Scott McPhee's work include Virus-based gene therapy research (14 papers), CAR-T cell therapy research (7 papers) and Viral Infectious Diseases and Gene Expression in Insects (7 papers). Scott McPhee is often cited by papers focused on Virus-based gene therapy research (14 papers), CAR-T cell therapy research (7 papers) and Viral Infectious Diseases and Gene Expression in Insects (7 papers). Scott McPhee collaborates with scholars based in United States, New Zealand and United Kingdom. Scott McPhee's co-authors include R. Jude Samulski, Paola Leone, Chengwen Li, Andrew Freese, Jade Samulski, Steven J. Gray, Dawn E. Bowles, David Shera, Mavis Agbandje‐McKenna and Jeremy S. Francis and has published in prestigious journals such as New England Journal of Medicine, Blood and Nature Biotechnology.

In The Last Decade

Scott McPhee

25 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott McPhee United States 16 1.6k 1.4k 332 326 176 27 2.2k
Peter Colosi United States 28 2.6k 1.6× 2.1k 1.5× 270 0.8× 455 1.4× 193 1.1× 46 3.5k
Fabienne Rolling France 29 2.3k 1.4× 1.8k 1.3× 214 0.6× 230 0.7× 325 1.8× 52 2.8k
R. Jude Samulski United States 21 2.3k 1.4× 2.2k 1.6× 391 1.2× 534 1.6× 171 1.0× 33 3.0k
Joshua C. Grieger United States 17 1.9k 1.2× 1.7k 1.3× 290 0.9× 383 1.2× 238 1.4× 21 2.6k
David M. Markusic United States 26 1.5k 0.9× 1.4k 1.0× 196 0.6× 641 2.0× 64 0.4× 54 2.4k
Cathryn Mah United States 29 2.2k 1.4× 2.0k 1.5× 466 1.4× 371 1.1× 142 0.8× 38 3.3k
Brian Tomkowicz United States 17 988 0.6× 508 0.4× 115 0.3× 345 1.1× 115 0.7× 22 1.8k
Sylvie Boutin France 13 1.1k 0.7× 1.2k 0.9× 256 0.8× 453 1.4× 102 0.6× 18 1.6k
Christian Hinderer United States 21 1.4k 0.9× 1.4k 1.0× 226 0.7× 302 0.9× 240 1.4× 32 2.3k
Douglas M. McCarty United States 32 2.5k 1.5× 2.5k 1.8× 359 1.1× 386 1.2× 236 1.3× 59 3.9k

Countries citing papers authored by Scott McPhee

Since Specialization
Citations

This map shows the geographic impact of Scott McPhee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott McPhee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott McPhee more than expected).

Fields of papers citing papers by Scott McPhee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott McPhee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott McPhee. The network helps show where Scott McPhee may publish in the future.

Co-authorship network of co-authors of Scott McPhee

This figure shows the co-authorship network connecting the top 25 collaborators of Scott McPhee. A scholar is included among the top collaborators of Scott McPhee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott McPhee. Scott McPhee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McPhee, Scott, et al.. (2023). Lightweighting large optomechanical structures in astronomy instrumentation utilising generative design and additive manufacturing. ePubs (Science and Technology Facilities Council, Research Councils UK). 12188. 21–21.
2.
Konkle, Barbara A., Christopher Walsh, Miguel A. Escobar, et al.. (2020). BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 137(6). 763–774. 138 indexed citations
3.
Li, Chengwen, Matthew L. Hirsch, Wuping Li, et al.. (2015). Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. Molecular Therapy. 24(1). 53–65. 40 indexed citations
4.
Wang, Mian, et al.. (2015). Prediction of adeno-associated virus neutralizing antibody activity for clinical application. Gene Therapy. 22(12). 984–992. 42 indexed citations
6.
Ishikawa, Kiyotake, Kenneth Fish, Lisa Tilemann, et al.. (2014). Cardiac I-1c Overexpression With Reengineered AAV Improves Cardiac Function in Swine Ischemic Heart Failure. Molecular Therapy. 22(12). 2038–2045. 59 indexed citations
7.
Leone, Paola, David Shera, Scott McPhee, et al.. (2012). Long-Term Follow-Up After Gene Therapy for Canavan Disease. Science Translational Medicine. 4(165). 165ra163–165ra163. 205 indexed citations
8.
Bowles, Dawn E., Scott McPhee, Chengwen Li, et al.. (2011). Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector. Molecular Therapy. 20(2). 443–455. 306 indexed citations
9.
Leung, Cary H., Michele A. Kliem, Scott McPhee, et al.. (2011). Assessment of Hippocampal Adeno-Associated Viral Vector Gene Delivery via Frameless Stereotaxis in a Nonhuman Primate. Stereotactic and Functional Neurosurgery. 89(5). 275–285. 3 indexed citations
10.
Monahan, Paul E., Junjiang Sun, Tong Gui, et al.. (2011). Employing Factor IX Variants to Avoid Limitations Imposed by Immune Recognition of AAV Vector in Hemophilia B Gene Therapy. Blood. 118(21). 3124–3124. 3 indexed citations
11.
Campbell, Katherine, Louise R. Rodino‐Klapac, Zarife Sahenk, et al.. (2010). Revertant muscle fibers expressing dystrophin do not tolerize the immune system in Duchenne muscular dystrophy: lessons learned from a Phase I clinical trial (96.9). The Journal of Immunology. 184(Supplement_1). 96.9–96.9. 1 indexed citations
12.
Mendell, Jerry R., Katherine Campbell, Louise R. Rodino‐Klapac, et al.. (2010). Dystrophin Immunity in Duchenne's Muscular Dystrophy. New England Journal of Medicine. 363(15). 1429–1437. 455 indexed citations
13.
Asokan, Aravind, Jana L. Phillips, Chengwen Li, et al.. (2009). Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nature Biotechnology. 28(1). 79–82. 194 indexed citations
14.
McPhee, Scott, et al.. (2009). Gene therapy for cardiomyocytes, a heart beat away. Gene Therapy. 16(6). 707–708. 3 indexed citations
15.
Janson, Christopher G., Edwin H. Kolodny, Srinivasa Raghavan, et al.. (2006). Mild‐onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene. Annals of Neurology. 59(2). 428–431. 35 indexed citations
16.
Francis, Jeremy S., et al.. (2006). Novel role for aspartoacylase in regulation of BDNF and timing of postnatal oligodendrogenesis. Journal of Neuroscience Research. 84(1). 151–169. 19 indexed citations
17.
McPhee, Scott, C. G. Janson, Chuang Li, et al.. (2006). Immune responses to AAV in a phase I study for Canavan disease. The Journal of Gene Medicine. 8(5). 577–588. 187 indexed citations
18.
McPhee, Scott, Jeremy S. Francis, C. G. Janson, et al.. (2005). Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Molecular Brain Research. 135(1-2). 112–121. 34 indexed citations
19.
Leone, Paola, C. G. Janson, Zhiyue Wang, et al.. (2000). Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Annals of Neurology. 48(1). 27–38. 114 indexed citations
20.
Leone, Paola, Scott McPhee, Christopher G. Janson, et al.. (2000). Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recovery in Parkinsonian rats. Neuroreport. 11(6). 1145–1151. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026